Ray of hope in Merck cost-cutting gloom: New cancer-immunotherapy data

While headlines focused on Merck's ($MRK) 8,500-job, $2.5 billion restructuring yesterday, the pharma giant quietly posted promising early-stage data on what has become its brightest pipeline prospect: the cancer immunotherapy MK-3475. Report

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.